Deficient DNA damage signaling leads to chemoresistance to cisplatin in oral cancer

Molecular Cancer Therapeutics

Volumn 11, Issue 11, 2012, Pages 2401-2409

  Wang, Ling ^a   Mosel, Adam J ^a   Oakley, Gregory G ^a   Peng, Aimin ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; ATM PROTEIN; CCT 007093; CISPLATIN; PROTEIN P53; REGULATOR PROTEIN; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG; WILD TYPE P53 INDUCED PHOSPHATASE 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER GENE THERAPY; CANCER GROWTH; CANCER MODEL; CANCER RESISTANCE; CARCINOMA CELL; CHEMOSENSITIZATION; CONTROLLED STUDY; DNA DAMAGE; DNA REPAIR; DRUG RESPONSE; DRUG TARGETING; FEMALE; GENE SILENCING; GENE TARGETING; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; LARYNX SQUAMOUS CELL CARCINOMA; MOUSE; MOUTH SQUAMOUS CELL CARCINOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; RNA INTERFERENCE; UPREGULATION;

ANIMALS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL PROLIFERATION; CISPLATIN; DNA DAMAGE; DNA REPAIR; DRUG RESISTANCE, NEOPLASM; GENE KNOCKDOWN TECHNIQUES; HUMANS; MICE; MICE, NUDE; MOUTH NEOPLASMS; PHOSPHOPROTEIN PHOSPHATASES; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION;

EID: 84869221003     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-12-0448     Document Type: Article

References (42)

1. Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, Kepp O, et al. Molecular mechanisms of cisplatin resistance. Oncogene 2012;31:1869-83.
2. Caponigro F, Milano A, Basile M, Ionna F, Iaffaioli RV. Recent advances in head and neck cancer therapy: the role of new cytotoxic and molecular-targeted agents. Curr Opin Oncol 2006;18:247-52. (Pubitemid 43740419)
3. Zhou BB, Anderson HJ, Roberge M. Targeting DNA checkpoint kinases in cancer therapy. Cancer Biol Ther 2003;2:S16 -22.
4. Shiloh Y. ATM and related protein kinases: safeguarding genome integrity. Nat Rev Cancer 2003;3:155-68. (Pubitemid 37328868)
5. Uziel T, Lerenthal Y, Moyal L, Andegeko Y, Mittelman L, Shiloh Y. Requirement of the MRN complex for ATM activation by DNA damage. EMBO J 2003;22:5612-21. (Pubitemid 37279970)
6. Carson CT, Schwartz RA, Stracker TH, Lilley CE, Lee DV, Weitzman MD. The Mre11 complex is required for ATM activation and the G2/M checkpoint. EMBO J 2003;22:6610-20. (Pubitemid 38009607)
7. Zou L, Elledge SJ. Sensing DNA damage through ATRIP recognition of RPA-ssDNA complexes. Science 2003;300:1542-8. (Pubitemid 36682880)
8. Kumagai A, Lee J, Yoo HY, Dunphy WG. TopBP1 activates the ATRATRIP complex. Cell 2006;124:943-55.
9. Prendergast AM, Cruet-Hennequart S, Shaw G, Barry FP, Carty MP. Activation of DNA damage response pathways in human mesenchymal stem cells exposed to cisplatin or gamma-irradiation. Cell Cycle 2011;10:3768-77.
10. Pabla N, Ma Z, McIlhatton MA, Fishel R, Dong Z. hMSH2 recruits ATR to DNA damage sites for activation during DNA damage-induced apoptosis. J Biol Chem 2011;286:10411-8.
11. Liang X, Guo Y, Figg WD, Fojo AT, Mueller MD, Yu JJ. The role of wild-type p53 in cisplatin-induced Chk2 phosphorylation and the inhibition of platinum resistance with a Chk2 inhibitor. Chemother Res Pract 2011;2011:715469.
12. Peng A, Maller JL. Serine/threonine protein phosphatases in the DNA damage response and cancer. Oncogene 2010;29:5977-88.
13. Lu XB, Nguyen TA, Moon SH, Darlington Y, Sommer M, Donehower LA. The type 2C phosphatase Wip1: an oncogenic regulator of tumor suppressor and DNA damage response pathways. Cancer Metastasis Rev 2008;27:123-35.
14. Le Guezennec X, Bulavin DV. WIP1 phosphatase at the crossroads of cancer and aging. Trends Biochem Sci 2010;35:109-14.
15. Brenner JC, Graham MP, Kumar B, Saunders LM, Kupfer R, Lyons RH, et al. Genotyping of 73 UM-SCC head and neck squamous cell carcinoma cell lines. Head Neck 2010;32:417-26.
16. Manthey KC, Glanzer JG, Dimitrova DD, Oakley GG. Hyperphosphorylation of replication protein a in cisplatin-resistant and -sensitive head and neck squamous cell carcinoma cell lines. Head Neck 2010;32:636-45.
17. Peng A, Wang L, Fisher LA. Greatwall and Polo-like kinase 1 coordinate to promote checkpoint recovery. J Biol Chem 2011;286:28996 - 9004.
18. Wang L, Fisher LA, Wahl JK 3rd, Peng A. Monoclonal antibodies against Xenopus greatwall kinase. Hybridoma 2011;30:469-74.
19. Spanswick VJ, Hartley JM, Ward TH, Hartley JA. Measurement of drug-induced DNA interstrand crosslinking using the single-cell gel electrophoresis (comet) assay. Methods Mol Med 1999;28:143-54.
20. Fiscella M, Zhang H, Fan S, Sakaguchi K, Shen S, Mercer WE, et al. Wip1, a novel human protein phosphatase that is induced in response to ionizing radiation in a p53-dependent manner. Proc Natl Acad Sci U S A 1997;94:6048 -53.
21. Bradford CR, Zhu S, Ogawa H, Ogawa T, Ubell M, Narayan A, et al. P53 mutation correlates with cisplatin sensitivity in head and neck squamous cell carcinoma lines. Head Neck 2003;25:654-61. (Pubitemid 36909750)
22. Yoda A, Toyoshima K, Watanabe Y, Onishi N, Hazaka Y, Tsukuda Y, et al. Arsenic trioxide augments Chk2/p53-mediated apoptosis by inhibiting oncogenic Wip1 phosphatase. J Biol Chem 2008;283:18969-79.
23. Rayter S, Elliott R, Travers J, Rowlands MG, Richardson TB, Boxall K, et al. A chemical inhibitor of PPM1D that selectively kills cells overexpressing PPM1D. Oncogene 2008;27:1036-44. (Pubitemid 351253192)
24. Platanias LC. Biological responses to arsenic compounds. J Biol Chem 2009;284:18583-7.
25. Parikh RA, White JS, Huang X, Schoppy DW, Baysal BE, Baskaran R, et al. Loss of distal 11q is associated with DNA repair deficiency and reduced sensitivity to ionizing radiation in head and neck squamous cell carcinoma. Genes Chromosomes Cancer 2007;46:761-75. (Pubitemid 46912347)
26. He Y, Chen Q, Li B. ATM in oral carcinogenesis: association with clinicopathological features. J Cancer Res Clin Oncol 2008;134:1013-20.
27. Lee KW, Tsai YS, Chiang FY, Huang JL, Ho KY, Yang YH, et al. Lower ataxia telangiectasia mutated (ATM) mRNA expression is correlated with poor outcome of laryngeal and pharyngeal cancer patients. Ann Oncol 2011;22:1088-93.
28. Jiang H, Reinhardt HC, Bartkova J, Tommiska J, Blomqvist C, Nevanlinna H, et al. The combined status of ATM and p53 link tumor development with therapeutic response. Genes Dev 2009;23:1895-909.
29. Gumy-Pause F, Wacker P, Sappino AP. ATM gene and lymphoid malignancies. Leukemia 2004;18:238-42. (Pubitemid 38240037)
30. Haidar MA, Kantarjian H, Manshouri T, Chang CY, O'Brien S, Freireich E, et al. ATM gene deletion in patients with adult acute lymphoblastic leukemia. Cancer 2000;88:1057-62. (Pubitemid 30127666)
31. Austen B, Skowronska A, Baker C, Powell JE, Gardiner A, Oscier D, et al. Mutation status of the residual ATM allele is an important determinant of the cellular response to chemotherapy and survival in patients with chronic lymphocytic leukemia containing an 11q deletion. J Clin Oncol 2007;25:5448-57. (Pubitemid 350232222)
32. Ripolles L, Ortega M, Ortuno F, Gonzalez A, Losada J, Ojanguren J, et al. Genetic abnormalities and clinical outcome in chronic lymphocytic leukemia. Cancer Genet Cytogenet 2006;171:57-64. (Pubitemid 44635753)
33. Park JY, Song JY, Kim HM, Han HS, Seol HS, Jang SJ, et al. p53-Independent expression of wild-type p53-induced phosphatase 1 (Wip1) in methylmethane sulfonate-treated cancer cell lines and human tumors. Int J Biochem Cell Biol 2012;44:896-904.
34. Lowe JM, Cha H, Yang Q, Fornace AJ Jr. Nuclear factor-kappaB (NF-kappaB) is a novel positive transcriptional regulator of the oncogenic Wip1 phosphatase. J Biol Chem 2010;285:5249 - 57.
35. Han HS, Yu E, Song JY, Park JY, Jang SJ, Choi J. The estrogen receptor alpha pathway induces oncogenic Wip1 phosphatase gene expression. Mol Cancer Res 2009;7:713-23.
36. Yagi H, Chuman Y, Kozakai Y, Imagawa T, Takahashi Y, Yoshimura F, et al. A small molecule inhibitor of p53-inducible protein phosphatase PPM1D. Bioorg Med Chem Lett 2012;22:729-32.
37. Ali AY, Abedini MR, Tsang BK. The oncogenic phosphatase PPM1D confers cisplatin resistance in ovarian carcinoma cells by attenuating checkpoint kinase 1 and p53 activation. Oncogene 2011;31:2175 - 86.
38. Kong W, Jiang X, Mercer WE. Downregulation of Wip-1 phosphatase expression in MCF-7 breast cancer cells enhances doxorubicin-induced apoptosis through p53-mediated transcriptional activation of Bax. Cancer Biol Ther 2009;8:555-63.
39. Goloudina AR, Tanoue K, Hammann A, Fourmaux E, Le Guezennec X, Bulavin DV, et al. Wip1 promotes RUNX2-dependent apoptosis in p53-negative tumors and protects normal tissues during treatment with anticancer agents. Proc Natl Acad Sci U S A 2012;109:E68 -75.
40. Bauer JA, Trask DK, Kumar B, Los G, Castro J, Lee JS, et al. Reversal of cisplatin resistance with a BH3 mimetic, (-)-gossypol, in head and neck cancer cells: role of wild-type p53 and Bcl-xL. Mol Cancer Ther 2005;4:1096-104. (Pubitemid 41079103)
41. Verstovsek S, Giles F, Quintas-Cardama A, Perez N, Ravandi-Kashani F, Beran M, et al. Arsenic derivatives in hematologic malignancies: a role beyond acute promyelocytic leukemia? Hematol oncol 2006;24:181-8. (Pubitemid 46032891)
42. Emadi A, Gore SD. Arsenic trioxide-an old drug rediscovered. Blood Rev 2010;24:191-9.